Wolff H
Klinik für Chirurgie des Bereiches Medizin (Charité), Humboldt-Universität zu Berlin.
Langenbecks Arch Chir Suppl II Verh Dtsch Ges Chir. 1990:157-60.
33 patients with liver malignancy underwent transplantations. The overall survival rate 1, 2 and 5 years after transplantation was 42.4%, 30% and 24.2%, respectively. These figures agree with those of other centres. 16 patients with primary hepatocellular carcinoma had a median survival of 2 years and 2 months and a 5-year-survival rate of 37.5%, the longest followup being more than 11 years. 10 patients with cholangiocellular carcinoma had a 5-year-survival rate of only 10%, the longest followup being more than 6 years. Patients with liver sarcoma and liver metastasis had a low survival rate and high tumor recurrence. Transplantation is generally well accepted for primary hepatocellular carcinoma. For other malignancies it should be considered an exception, provided that extrahepatic tumor spread has been ruled out.
33例肝脏恶性肿瘤患者接受了移植手术。移植后1年、2年和5年的总生存率分别为42.4%、30%和24.2%。这些数据与其他中心的数据一致。16例原发性肝细胞癌患者的中位生存期为2年零2个月，5年生存率为37.5%，最长随访时间超过11年。10例胆管细胞癌患者的5年生存率仅为10%，最长随访时间超过6年。肝脏肉瘤和肝转移患者的生存率较低，肿瘤复发率较高。原发性肝细胞癌患者一般对移植接受度较高。对于其他恶性肿瘤，只有在排除肝外肿瘤扩散的情况下，才应将移植视为例外情况。
